

**This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.**

**The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.**

**These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.**

**Some data have been adjusted to facilitate estimates of standard indicators across countries.**

**Details of the process for searching, grading and including data, along with their interpretation, are detailed in:**

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

**For more information on the Reference Group, please go to: [www.IDURefGroup.Com](http://www.IDURefGroup.Com)**

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
<b>1. Needle and syringe programs (NSPs)</b>	<b>5</b>
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
<b>2. Opioid substitution programs (OST)</b>	<b>13</b>
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

<b>Section</b>	<b>Page</b>
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
<b>3. Other Drug Treatment (ODT)</b>	<b>35</b>
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
<b>4. HIV testing and counselling (T&amp;C)</b>	<b>51</b>
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

<b>Section</b>	<b>Page</b>
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
<b>5. Anti-retro-viral (ARV) treatment</b>	<b>54</b>
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
<b>6. Condoms</b>	<b>57</b>
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

## Russian Federation (Eastern Europe)

### Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	1.31	1.78	2.33
Year of IDU prevalence estimate	2007		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	0.3	37.15	74
Year of HIV prevalence among IDU estimate	2003		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	101 788 353 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	1 335 500	1 815 500	2 372 500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	4006	674458	1 755 650

**1. Needle and syringe programs (NSPs)****NSP 1: Availability of NSPs**

<b>Are NSPs available?</b>	Yes
<b>Comments</b>	
<b>Most recent year of documentation</b>	2009
<b>Reference</b>	See references for other NSP indicators
<b>When were NSPs first introduced?</b>	
<b>Reference</b>	
<b>Are needles and syringes available for purchase from pharmacies?</b>	Yes
<b>Most recent year of documentation</b>	2009
<b>Reference</b>	Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.

## NSP 2: Number of NSP sites

<b>Data reported</b>	33 sites by Russian Harm Reduction Network 22 sites by Open health Institute 15 sites by Russian health Care Foundation		
<b>Year of reported data</b>	2009		
<b>Reference</b>	<p>Semenchenko, M. (Coordinator for Russia), UNAIDS Country office Russia,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 19 May 2009.</p> <p>Aksenov, P. (Executive Director), Russian Harm Reduction Network (RHRN),. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 16 May 2009.</p> <p>Varentzov, I. (HIV/AIDS Program Coordinator GFATM Project), Russian Health Care Foundation,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May.</p> <p>Djuma, V. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May 2009.</p> <p>Zaitseva, E. (Global Fund Project Manager), Open Health Institute. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 Sep 2009.</p>		
<b>Adjustments</b>	Assumed counts of all site are mutually exclusive. Total number of sites calculated.		
<b>Final/Adjusted data (to be used as indicator numerator)</b>	70		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 615 465 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 333 500	1 812 000	2 368 500
<b>INDICATOR: Number of NSP sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.03	0.04	0.05

## NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	Needles and syringes available for purchase from pharmacies but number of sites not available		
Year of reported data	2009		
Reference	Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	2007		
General population 15-64 years of age at year of reported data	101 615 465 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 333 500	1 812 000	2 368 500
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

## NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

<b>Data reported</b>	10 8066 IDUs accessing NSPs by Russian Harm Reduction Network and Open Health Institute in 2008  14 931 IDUs accessing NSPs by the Russian Health Care Foundation by the end of 2008		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Semenchenko, M. (Coordinator for Russia), UNAIDS Country office Russia,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 19 May 2009.  Varentzov, I. (HIV/AIDS Program Coordinator GFATM Project), Russian Health Care Foundation,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May.		
<b>Adjustments</b>	Assumed individual number of clients accessing services  assumed counts from different services are mutually exclusive		
<b>Final/Adjusted data (to be used as indicator numerator)</b>	122 997		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	5.2	6.8	9.2

## NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

<b>Data reported</b>	NSP present but number of occasions of service not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Semenchenko, M. (Coordinator for Russia), UNAIDS Country office Russia,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 19 May 2009.</p> <p>Varentzov, I. (HIV/AIDS Program Coordinator GFATM Project), Russian Health Care Foundation,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

<b>Data reported</b>	6 464 460 syringes/needles distributed in 2008 by Russian Harm Reduction Network and Open health Institute  440000 needles/syringes distributed by NSPs of the Russian Health Care Foundation		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Semenchenko, M. (Coordinator for Russia), UNAIDS Country office Russia,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 19 May 2009.  Varentzov, I. (HIV/AIDS Program Coordinator GFATM Project), Russian Health Care Foundation,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May.		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	6 904 460		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	2.91	3.8	5.17

**NSP: All documents reviewed**

Aceijas, C., M. Hickman, et al. (2007). "Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.[see comment]." *Addiction* 102(8): 1244-50.

Aksenov, P. (Executive Director), Russian Harm Reduction Network (RHRN),. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 16 May 2009.

AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from <http://www.avert.org/needle-exchange.htm>

Badrieva, L., E. Karchevsky, et al. (2007). "Lower injection-related HIV-1 risk associated with participation in a harm reduction program in Kazan, Russia." *AIDS Education & Prevention* 19(1): 13-23.

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Djuma, V. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May 2009.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Eurasian Harm Reduction Network. (2008). "Russia: Kaliningrad drug control department hinders implementation of syringe exchange programmes." Retrieved 1 September, 2008, from <http://www.harm-reduction.org/news/52-russia-kaliningrad-drug-control-department-hinders-implementation-of-syringe-exchange-programmes.html>.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

Human Rights Watch (2004). "Russia: harsh drug policies fuel AIDS epidemic." Retrieved 30th November, 2008, from <http://www.hrw.org/en/news/2004/04/26/russia-harsh-drug-policies-fuel-aids-epidemic>.

International Harm Reduction Association (2008). Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics:

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

International Harm Reduction Development Program (2008). Harm reduction developments 2008. New York.

Irwin, K., E. Karchevsky, et al. (2006). "Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation." *Substance Use & Misuse* 41(6-7): 979-99.

Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." *Harm Reduction Journal* 4(1): 14.

Jekabsons, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.

Joint United Nations Programme on HIV/AIDS (UNAIDS) (2005). AIDS epidemic update. Geneva, Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organisation (WHO).

Platt, L., M. Hickman, et al. (2004). "The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage." *Addiction* 99(11): 1430-8.

Rhodes, T., A. Judd, et al. (2004). "Injecting equipment sharing among injecting drug users in Togliatti City, Russian Federation: maximizing the protective effects of syringe distribution." *Journal of Acquired Immune Deficiency Syndromes: JAIDS* 35(3): 293-300.

Rhodes, T., L. Platt, et al. (2006). "Street Policing, Injecting Drug Use and Harm Reduction in a Russian City: A Qualitative Study of Police Perspectives." *Journal of Urban Health* 83(5): 911-925.

Sarang, A., R. Stuijkyte, et al. (2007). "Implementation of harm reduction in Central and Eastern Europe and Central Asia." *International Journal of Drug Policy* 18(2): 129-35.

Sarang, A., T. Rhodes, et al. (2008). "Access to syringes in three Russian cities: implications for syringe distribution and coverage." *International Journal of Drug Policy* 19 Suppl 1: S25-36.

Semenchenko, M. (Coordinator for Russia), UNAIDS Country office Russia,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 19 May 2009.

Sharma, M., D. Burrows, et al. (2007). "Coverage of HIV prevention programmes for injection drug users: confusions, aspirations, definitions and ways forward." *International Journal of Drug Policy* 18(2): 92-8.

This report was generated by the Reference Group to the United Nations on HIV and injecting drug use. For details of methods and interpretation, see: Mathers, B., L. Degenhardt, et al. (2010). "HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage." *The Lancet*. DOI:10.1016/S0140-6736(10)60232-2. 11 of 59

**NSP: All documents reviewed**

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

UNAIDS (2008). Eastern Europe and Central Asia mapping prevention interventions in the CIS region.

Varentzov, I. (HIV/AIDS Program Coordinator GFATM Project), Russian Health Care Foundation,. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Russian Federation". Moscow, Russia, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 26 May.

Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

World Bank Global HIV/AIDS Program (2006). Preventing HIV infection in Russia: best practices in harm reduction programs. HIV/AIDS - Getting Results. The world Bank.

Zaitseva, E. (Global Fund Project Manager), Open Health Institute. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 Sep 2009.

**2. Opioid substitution treatment (OST)****OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	No
Comments	
Most recent year of documentation	2008
Reference	Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .  Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.  Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.
When was agonist OST first available?	
Reference	

**OST 2: Availability of methadone maintenance treatment (MMT)**

Is MMT available?	No
Comments	
Most recent year of documentation	2008
Reference	Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .  Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.  Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.
When was MMT first available?	
Reference	

**OST 3: Availability of buprenorphine maintenance treatment (BMT)**

Is BMT available?	No
Comments	
Most recent year of documentation	2008
Reference	Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .  Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.  Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.
When was BMT first available?	
Reference	

## OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	No
Comments	
Most recent year of documentation	2008
Reference	Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .  Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.  Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.
When were other forms of OST first available?	
Reference	

## OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

## OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

## OST 7: Total number of all sites providing OST

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Number of OST sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 8: Number of sites providing MMT

<b>Data reported</b>	MMT not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Number of MMT sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 9: Number of sites providing BMT

Data reported	BMT not available		
Year of reported data	2008		
Reference	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	101 788 353 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0	0	0

## OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

## OST 11: Number of all clients in any OST at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 12: Number of all clients in MMT at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 13: Number of all clients in BMT at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 14: Number of all clients in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	101 788 353 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	0	0	0

## OST 15: Number of IDUs in any OST at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs in OST at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 16: Number of IDUs in MMT at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs in MMT at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 17: Number of IDUs in BMT at a single point in time

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs in BMT at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	101 788 353 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	0	0	0

## OST 19: Number of all clients receiving any OST in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 20: Number of all clients receiving MMT in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 21: Number of all clients receiving BMT in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 22: Number of all clients receiving other forms of OST in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 23: Number of IDUs receiving any OST in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs receiving OST in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 24: Number of IDUs receiving MMT in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs receiving MMT in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 25: Number of IDUs receiving BMT in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs receiving BMT in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

## OST 26: Number of IDUs receiving other forms of OST in a 12 month period

<b>Data reported</b>	OST not available		
<b>Year of reported data</b>	2008		
<b>Reference</b>	<p>Barrett, D., R. Lines, et al. (2008). Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .</p> <p>Vyshemirskaya, I., Osipenko, V, Koss, A, &amp; Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.</p> <p>Human Rights Watch (2008) World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment.</p>		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

**OST: All documents reviewed**

Barrett, D., R. Lines, et al. (2008). *Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy*. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Csete, J. and D. Wolfe (2007). *Closed to Reason: The International Narcotics Control Board and HIV/AIDS*. Toronto and New York, Canadian HIV/AIDS Legal Network and the International Harm Reduction Development Program of the Open Society Institute.

Human Rights Watch (2004). "Russia: harsh drug policies fuel AIDS epidemic." Retrieved 30th November, 2008, from <http://www.hrw.org/en/news/2004/04/26/russia-harsh-drug-policies-fuel-aids-epidemic>.

Human Rights Watch (2007). *Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment*. New York, Human Rights Watch. 19;7(D).

Human Rights Watch (2008) *World AIDS day: address needs of drug users. Ensure access to HIV prevention and treatment*.

International Harm Reduction Association (IHRA) (2007). *Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm*, Warsaw, Poland.

International Harm Reduction Development Program (2008). *Harm reduction developments 2008*. New York.

International Treatment Preparedness Coalition (ITPC) (2007). *Missing the target #5: improving AIDS drug access and advancing health care for all*, International Treatment Preparedness Coalition (ITPC).

Mendelevich, P., M. Donoghoe, et al. (2007). *Social attitudes towards Opioid Substitution Therapy and its role in advocacy work in the Russian Federation*. International Harm Reduction Conference 2007.

Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). *HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services*. Kaliningrad, Rapid Policy Assessment and Response: 90.

**3. Other drug treatment (ODT)****ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

<b>Is detoxification available?</b>	Yes		
<b>Number of sites - data reported</b>	192 inpatient detox sites		
<b>Year of reported data</b>	2005		
<b>Reference</b>	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	192		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 827 872 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 336 000	1 816 000	2 373 500
<b>INDICATOR: Number of detoxification sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.08	0.11	0.14

## ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2005		
Reference	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 827 872 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2005		
Reference	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 827 872 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

## ODT 2 - Residential rehabilitation

## ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	yes		
Number of sites - data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 821 293 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 821 293 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 821 293 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

## ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

## ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2009		
Reference	Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 615 465 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 333 500	1 812 000	2 368 500
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

### ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

<b>Data reported</b>	Psychosocial support and counselling present but number not known		
<b>Year of reported data</b>	2009		
<b>Reference</b>	Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 615 465 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 333 500	1 812 000	2 368 500
<b>INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

### ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

<b>Data reported</b>	Psychosocial support and counselling present but number not known		
<b>Year of reported data</b>	2009		
<b>Reference</b>	Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 615 465 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 333 500	1 812 000	2 368 500
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## ODT 4 - Peer-based support groups

## ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	330 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	330		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 788 353 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	0.14	0.18	0.25

## ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 788 353 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

## ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 788 353 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High

## ODT 6 - Drug treatment in prisons

## ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

## ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

## ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

**ODT: All documents reviewed**

Babakian, G. (2005). "Positively abandoned: stigma and discrimination against HIV-positive mothers and their children in Russia." *Human Rights Watch* 17(4): 41.

Bobrova, N., R. Alcorn, et al. (2007). "Injection drug users' perceptions of drug treatment services and attitudes toward substitution therapy: a qualitative study in three Russian cities." *Journal of Substance Abuse Treatment* 33(4): 373-8.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." *BMC Public Health* 6(1): 54.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

Goliusov, A., Dementyeva, LA, Ladnaya, NN, Briko, NI, Tumanova, MS, Korzhayeva, NA, Semenchenko, MV, Nietzsche-Bell, A, & Kobzeva, VB (2008). Country Progress Report of the Russian Federation on the Implementation of the Declaration of Commitment on HIV/AIDS. Report period: January 2006-December 2007. Moscow, Ministry of Health and Social Development of the Russian Federation: 53.

Human Rights Watch (2007). Russia's Human Rights Obligation to Provide Evidence-based Drug Dependence Treatment. New York, Human Rights Watch. 19;7(D).

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Jekabsone, I. (Project Coordinator), UNODC. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Moscow, Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 30 Sep 2009.

Joint United Nations Programme on HIV/AIDS (UNAIDS) (2005). AIDS epidemic update. Geneva, Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organisation (WHO).

Needle, R., D. Burrows, et al. (2005). "Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users." *International Journal of Drug Policy* 16(Supplement 1): S45-S57.

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.

## 4. HIV testing and counselling (T&amp;C)

## T&amp;C 1: Availability of HIV T&amp;C

Is T&C available?	Yes
Most recent year of data	2009
Reference	Population Services International (2009). Russia HIV prevention activity targeted in October 2008 - September 2009.

## T&amp;C 2: Number of sites providing HIV T&amp;C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

## T&amp;C 3: Number of sites providing HIV T&amp;C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2009		
Reference	Population Services International (2009). Russia HIV prevention activity targeted in October 2008 - September 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 615 465 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 333 500	1 812 000	2 368 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## T&amp;C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported	285 330 IDUs tested for HIV in 12 month period		
Year of reported data	2008		
Reference	Ministry of Health and Social Development of the Russian Federation, Federal Service for Consumer Rights Protection and Human Welfare, Federal State Scientific Agency Central Research Institute of Epidemiology, Federal Scientific-methodological Centre for AIDS Prevention. (2009). HIV-Infection. Information Bulletin N. 33. Moscow. page 8 (in Russian).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	285 330		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 788 353 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High
	12.03	15.72	21.37

## T&amp;C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.
Data reported for both male and female IDUs	46% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	46%
Data reported for male IDUs	44% male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	44%
Data reported for female IDUs	50% female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	50%

**T&C: All documents reviewed**

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

Goliusov, A., Dementyeva, LA, Ladnaya, NN, Briko, NI, Tumanova, MS, Korzhayeva, NA, Semenchenko, MV, Nitzsche-Bell, A, & Kobzeva, VB (2008). Country Progress Report of the Russian Federation on the Implementation of the Declaration of Commitment on HIV/AIDS. Report period: January 2006-December 2007. Moscow, Ministry of Health and Social Development of the Russian Federation: 53.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Ministry of Health and Social Development of the Russian Federation, Federal Service for Consumer Rights Protection and Human Welfare, Federal State Scientific Agency Central Research Institute of Epidemiology, Federal Scientific-methodological Centre for AIDS Prevention. (2009). HIV-Infection. Information Bulletin N. 33. Moscow. page 8 (in Russian).

Population Services International (2009). Russia HIV prevention activity targeted in October 2008 - September 2009.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

Vyshemirskaya, I., Osipenko, V, Koss, A, & Burkhanova, O. (2008). HIV and Drug Policy in Kaliningrad: Risk, Silence and the Gap between Human Needs and Health Services. Kaliningrad, Rapid Policy Assessment and Response: 90.

**5. Anti-retro-viral (ARV) treatment****ARV 1: Number of sites providing ARV treatment**

<b>Data reported</b>	14 sites operated by OHI funded by GFATM in 10 regions [No additional information on other sites]		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Zaitseva, E. (Global Fund Project Manager), Open Health Institute. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 Sep 2009		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	14(l)		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1.31	1.78	2.33
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	101 788 353 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	1 335 500	1 815 500	2 372 500
<b>HIV among IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.30	37.15	74
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
<b>Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	4006	674458	1 755 650
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.01	0.01	0.01
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0.01	0.02	3.49

## ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	3026 clients receiving ART at OHI operated sites at the end of 2008, of these 44% are IDUs		
Year of reported data	2008		
Reference	Zaitseva, E. (Global Fund Project Manager), Open Health Institute. Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check". Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 Sep 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1331		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 788 353 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 335 500	1 815 500	2 372 500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	0.30	37.15	74
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	4006	674458	1 755 650
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	0.08	0.20	33.22

## ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

**ARV: All documents reviewed**

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

AVERT. (2008). "HIV and AIDS in Russian Eastern Europe & Central Asia." Retrieved 30 November, 2008, from <http://www.avert.org/aids-russia.htm>

Barrett, D., R. Lines, et al. (2008). *Recalibrating the Regime: The Need for a Human Rights-based Approach to International Drug Policy*. Oxford, Human Rights Watch, the International Harm Reduction Association and the Canadian HIV/AIDS Legal Network. .

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.

European AIDS Treatment Group (2008). *Antiretroviral treatment for injecting drug users in Central and Eastern Europe*.

Human Rights Watch (2004). "Russia: harsh drug policies fuel AIDS epidemic." Retrieved 30th November, 2008, from <http://www.hrw.org/en/news/2004/04/26/russia-harsh-drug-policies-fuel-aids-epidemic>.

International Harm Reduction Association (2008). *Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics*:

International Harm Reduction Association (IHRA) (2007). *Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland*.

International Treatment Preparedness Coalition (ITPC) (2007). *Missing the target #5: improving AIDS drug access and advancing health care for all, International Treatment Preparedness Coalition (ITPC)*.

UNAIDS (2008). *Eastern Europe and Central Asia mapping prevention interventions in the CIS region*.

Zaitseva, E. (Global Fund Project Manager), Open Health Institute. *Personal Communication: Response to "Russian Federation - UN Reference Group - Final Data Check"*. Russian Federation, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 28 Sep 2009.

## 6. Condoms

### Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	Condoms are distributed at low threshold NSP facilities.
Year	2007
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

### Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 821 293 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

## Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	1.31	1.78	2.33
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	101 821 293 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1 336 000	1 816 000	2 373 500
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

**Condoms: All documents reviewed**

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Human Rights Watch (2004). "Russia: harsh drug policies fuel AIDS epidemic." Retrieved 30th November, 2008, from <http://www.hrw.org/en/news/2004/04/26/russia-harsh-drug-policies-fuel-aids-epidemic>.

Population Services International (2009). Russia HIV prevention activity targeted in October 2008 - September 2009.

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

UNAIDS (2008). Eastern Europe and Central Asia mapping prevention interventions in the CIS region.

World Bank Global HIV/AIDS Program (2006). Preventing HIV infection in Russia: best practices in harm reduction programs. HIV/AIDS - Getting Results. The world Bank.